PD-1抑制剂联合FOLFOX4化疗方案治疗晚期胃癌的效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (584 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy of PD-1 inhibitor combined with Oxaliplatin and 5-fluorouracil (FOLFOX4) chemotherapy regimens in the treatment of advanced gastric cancer. Methods A total of 80 patients with advanced gastric cancer who admitted to the 960th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army from February 2016 to May 2019 were selected as study objects. They were divided into control group and study group, with 40 cases in each group. Control group was treated with FOLFOX4 chemotherapy regimens, and study group was treated with PD-1 inhibitor on the basis of control group. The curative effect, immune function, serum oncology indexes and adverse reactions were compared between two groups. Results The total effective rate of study group was higher than that of control group (P < 0.05). After treatment, carcinoembryonic antigen, carbohydrate antigen (CA) 125, and CA199 in two groups were lower than those before treatment, and study group was lower than control group (P < 0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ in both groups were lower than before treatment, and CD8+ was higher than before treatment. The levels of CD3+, CD4+, and CD4+/CD8+ in study group were higher than those in control group, and CD8+ was lower than those in control group (P < 0.05). There was no significant difference in the incidence of adverse reaction between two groups (P ＞ 0.05). Conclusion The combination of PD-1 inhibitor and FOLFOX4 chemotherapy regimens in the treatment of advanced gastric cancer have a significant effect, which can prevent tumor proliferation, reduce immunosuppression, and are safe and effective.

Key words： PD-1 inhibitor FOLFOX4 chemotherapy regimens Advanced gastric cancer Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Guili LIANG Xiuju DONG Min SHI Yanlong WEI Yan ZHONG Chen

Cite this article:

ZHENG Guili LIANG Xiuju DONG Min SHI Yanlong WEI Yan ZHONG Chen. Effect of PD-1 inhibitor combined with FOLFOX4 chemotherapy regimens in the treatment of advanced gastric cancer[J]. 中国医药导报, 2021, 18(8): 98-101.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I8/98

[1] 李光伟，曹芳，夏蕾，等.中药复方干预胃癌作用机制研究进展[J].国际中医中药杂志，2020，42（1）：86-89.
[2] Park KB，Park JY，Lee SS，et al. Chronological changes in quality of life and body composition after gastrectomy for locally advancedgastric cancer [J]. Ann Surg Treat Res，2020，98（5）：262-269.
[3] Zhang J，Dong R，Shen L. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer [J]. Chin J Cancer Res，2020，32（2）：263-270.
[4] Chen Z，Zhou Z，Hu Z，et al. Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer [J]. Oncol Lett，2018，15（1）：1079-1083.
[5] 李彦泽，王磊，陈志远，等.晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展[J].中国医药导报，2020，17（4）：40-43，51.
[6] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2015版）[J].中国癌症杂志，2015，25（9）：692-754.
[7] 赵爱珍，高世领，王玉强，等.中西医结合治疗中重度肺癌疼痛患者的疗效及生存观察[J].世界中西医结合杂志，2015，10（12）：1700-1702，1705.
[8] 唐滟，袁亚维.宫颈癌调强放射治疗同步化学药物治疗疗效及毒副反应分析[J].中国现代医学杂志，2015，25（36）：68-72.
[9] Behroozi J，Shahbazi S，Bakhtiarizadeh MR，et al. ADAR expression and copy number variation in patients with advanced gastric cancer [J]. BMC Gastroenterol，2020，20（1）：152.
[10] Dzunic M，Petkovic I，Cvetanovic A，et al. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4 [J]. J BUON，2020，25（1）：212-219.
[11] 贺小军，杨振宇，杜锡林，等.FOLFOX4化疗方案联合免疫治疗在中晚期肝癌中的应用价值（附2例报告）[J].现代肿瘤医学，2019，27（14）：2518-2523.
[12] Wang S，Wen F，Zhang P，et al. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer [J]. Radiat Oncol，2019，14（1）：113.
[13] 曾进龙，王志超，张海良.白介素-2联合FOLFOX6方案治疗晚期大肠癌的疗效分析及对VEGF的影响[J].中国医药科学，2016，6（14）：196-198.
[14] 李秀芹，张明奎，张斌斌，等.FOLFOX4化疗联合自拟中药扶正消积汤治疗中晚期结肠癌患者的临床效果及安全性[J].现代中西医结合杂志，2019，28（6）：635-637.
[15] 王俊伟，金心富，卢凯.腹腔镜切除术配合FOLFOX4新辅助化疗对直肠癌患者血清FAS、Tu M2-PK及T细胞亚群的影响[J].临床和实验医学杂志，2019，18（9）：981-985.
[16] 宋晓旭，赵光辉，齐卫卫，等.PD-L1介导胃癌免疫逃逸及其抑制剂在胃癌治疗中作用的研究进展[J].癌症进展，2019，17（23）：2761-2764.
[17] 易凡.PD-1/PD-L1抑制剂治疗胃癌的研究进展[J].中国肿瘤生物治疗杂志，2018，25（7）：737-741.
[18] 刘永军，徐稳.肿瘤免疫治疗中PD-1/PD-L1抑制剂的研究进展[J].中国医药导报，2018，15（16）：38-41.
[19] 韦炜，蒋敬庭，吴昌平.胃癌中PD-L1的表达及PD-1/PD-L1抑制剂应用研究进展[J].临床检验杂志，2017， 35（5）：363-365.
[20] 祁玲，黄镜.PD-1/PD-L1抑制剂在晚期胃癌治疗中的临床研究进展[J].中国生化药物杂志，2016，36（7）：4-7.
[21] 张绪超.PD-1/PD-L1免疫检查点抑制剂抗肿瘤治疗的潜在临床生物标志物[J].中华医学杂志，2017，97（32）：2551-2554.
[22] 朱伟政，梁瑜金，贾伟建.血清AFP、CEA、CA125、CA199联合检测在消化系统恶性肿瘤中的诊断价值[J].临床合理用药杂志，2020，13（7）：136-137.
[23] 陈伟军，陈灏庆，郭晓丹.CA199、CA125、CA153及CEA检测在消化道肿瘤诊断中的应用[J].现代诊断与治疗，2019，30（6）：943-944.
[24] 孙静.肿瘤标志物CA19-9、CA242、CEA和CA125联合检测在胰腺癌诊断中的意义[J].中国医药指南，2020， 18（18）：180-181.
[25] 杨泽，潘雪花，李波，等.PD-1/PD-L1抑制剂在胃癌中的研究现状[J].中国普外基础与临床杂志，2020，27（3）：379-382.
[26] 朱奎璇，官杰.程序性死亡蛋白-1/程序性死亡蛋白受体-1在临床疾病中的研究进展[J].中国当代医药，2020， 27（15）：40-43.
[27] 吴非，赵恩昊，曹晖.PD-1/PD-L1免疫治疗在胃癌中的研究进展[J].胃肠病学，2018，23（11）：685-688.